PROX1 and breast carcinoma: More specifically, Zhao et al. demonstrated that in cases of high VEGF-C-expressing tumors, PROX1 (among other lymphatic-specific markers) was overexpressed in uninvolved sentinel LNs in patients with breast cancer, compared to control LNs (p < 0.05) [30].